公开(公告)号：EP4406943A1

公开(公告)日：2024-07-31

申请号：EP22871955.5

申请日：2022-09-20

申请人： Hangzhou Phecdamed Co., Ltd.

发明人： XIA, Hongguang ,  FAN, Mengyang ,  CEN, Xufeng ,  XU, Xiaoyan ,  WU, Ronghai ,  LIU, Dong ,  TIAN, Zhen

IPC分类号： C07D305/08 ,  A61K31/38 ,  A61P31/04 ,  A61P9/10

CPC分类号： A61P9/10 ,  C07D305/08 ,  A61K31/38 ,  A61P31/04

摘要： The present application discloses small molecule compounds having a naphthylamine structure and an application thereof. In the present application, the structure of a compound having a structure as shown in general formula (I) is as shown in the drawing. The compound and the pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof that are provided by the present application or the pharmaceutical composition provided by the present application can selectively induce autophagy in damaged mitochondria without affecting or only weakly affecting normal mitochondria, and further have superior metabolic stability and pharmacokinetic properties, lower toxicity, and better druggability.

公开(公告)号：EP4406937A1

公开(公告)日：2024-07-31

申请号：EP22871956.3

申请日：2022-09-20

申请人： Hangzhou Phecdamed Co., Ltd.

发明人： XIA, Hongguang ,  FAN, Mengyang ,  CEN, Xufeng ,  XU, Xiaoyan ,  WU, Ronghai ,  LIU, Dong ,  TIAN, Zhen

IPC分类号： C07C323/52 ,  C07C381/10 ,  C07D305/08 ,  C07D285/10 ,  C07D285/16 ,  C07D249/08 ,  C07D257/04 ,  C07D333/34 ,  A61K31/192 ,  A61K31/337 ,  A61K31/381 ,  A61K31/265 ,  A61K31/222 ,  A61K31/4196 ,  A61K31/41 ,  A61K31/549 ,  A61K31/433 ,  A61P43/00

CPC分类号： A61K31/222 ,  A61K31/192 ,  A61K31/337 ,  A61K31/265 ,  A61K31/381 ,  A61K31/41 ,  A61K31/433 ,  A61K31/4196 ,  A61K31/549 ,  A61P43/00 ,  C07C323/52 ,  C07C381/10 ,  C07D249/08 ,  C07D257/04 ,  C07D285/10 ,  C07D285/16 ,  C07D305/08 ,  C07D333/34

摘要： The present application discloses a small-molecule compound having a naphthalenethiol ether structure, and a use thereof. Disclosed in the present application are a compound having a structure represented by general formula (I), a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof, a pharmaceutical composition containing the same, and a use thereof in the preparation of mitophagy inducer drugs. In the present application, the structure of the compound having the structure represented by general formula (I) is shown below. The compound and the pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, or the pharmaceutical composition provided in the present application can enhance the ability to induce mitophagy.